US President Donald Trump. Photo | courtesy.
Early this year, on March 13, the United States officially announced the removal of HIV funding in most African countries, especially those reliant on PEPFAR (President’s Emergency Plan for AIDS Relief).
This move affected a total of 15 countries in East and Southern Africa, with countries like Uganda, Tanzania, Zimbabwe, and Mozambique facing immediate disruption in HIV prevention and treatment services.
In Kenya, PEPFAR has been a key source of free antiretroviral drugs for over 1.4 million Kenyans, helping them manage HIV, improve their quality of life, and raising awareness through prevention campaigns. With the funding withdrawn, Kenya is expected to face several challenges and shifts in its HIV response:
Increased Cost for Patients
Many patients who relied on free ARVs are now in a dilemma as treatment costs have risen, forcing some of them to pay up to Sh10,700 per month to access medication. This is a direct disadvantage for those earning minimum wages.
Strain on Public Healthcare
The government is working to reallocate funds to sustain HIV treatment, but the transition may cause delays and shortages. As a result, some people may be affected in the short term, highlighting a significant disadvantage.
Uncertainties for Key Populations
Vulnerable groups, including those in marginalized communities such as the Ogiek in Mau Forest, the Endorois in Lake Bogoria, and the Ilchamus in Baringo, may struggle to access consistent treatment due to supply chain disruptions.
Potential Move to Private Providers
Public hospitals are now seeing a decline in the number of patients visiting them, as many are turning to private hospitals and pharmacies. However, these options are usually expensive and difficult to sustain for low-income individuals.
Stockouts and Rationing
Some healthcare facilities are experiencing shortages of the preferred ARV drugs, forcing patients to seek alternative medications that may have adverse side effects on their health.
Government Reallocation Efforts
The government is working hard to find alternative ways to counter the shortage, including a move to start producing ARVs locally. However, this may take time to implement, potentially at the cost of the lives of many people living with HIV.
